DCGI Approves Phase III Trial Of Bharat Biotech's Intranasal COVID-19 Vaccine
The Director Control General of India (DCGI) approved phase III trial of Intranasal COVID-19 vaccine, manufactured by Bharat Biotech. On January 4, the Subject Expert Committee (SEC) of the DCGI, approved the report, following which phase III trail will begin on 5,000 subject, 50% Covishield vaccinated people and 50% COVAXIN vaccinated people. If successful, the Intranasal vaccine will be used as booster shot, especially when nation is facing Omicron threat.